KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular subset characterized by historical disappointments in targeted treatment approaches such as farnesyl transferase inhibition, downstream MEK inhibition, and synthetic lethality screens. Unlike other important mutati...

Full description

Bibliographic Details
Main Authors: Helen Adderley, Fiona H. Blackhall, Colin R. Lindsay
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419301288

Internet

http://www.sciencedirect.com/science/article/pii/S2352396419301288

Similar Items